secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001437749-25-007383
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q4 2024 revenue $14.2M (down 3% YoY); net loss narrows to $4.6M; submits AYON 510(k) ahead of schedule
--------------------------------------------------------------------------------

- Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).
- Net loss Q4 $4.6M ($0.12 per share) vs $9.6M loss in Q4 2023; adjusted EBITDA loss $2.2M vs $4.7M.
- Full year 2024 net loss $23.5M ($0.66 per share) vs $18.7M; adjusted EBITDA loss $14.3M vs $13.4M.
- Submitted 510(k) for AYON Body Contouring System ~90 days early; planned launch back half 2025 pending clearance.
- Cost restructuring: workforce reduced ~25%, annual savings ~$4.3M. 2025 guidance: revenue $47.6-49.0M, opEx <$40M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774925007383/0001437749-25-007383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774925007383/apyx20241230_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer